SCHEMBL3504810

SCHEMBL3504810

COc1ccc2c(NCCN3CCOCC3)noc2c1Br

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 5/20 0.48
▸ CYP3A4 P08684 5/20 0.48
▸ CYP2D6 P10635 5/20 0.48
▸ CLK4 Q9HAZ1 4/20 0.48
▸ HSD17B10 Q99714 4/20 0.48
▸ LMNA P02545 2/20 0.48
▸ HIF1A Q16665 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ ALDH1A1 P00352 4/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ ATM Q13315 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ USP2 O75604 4/20 0.46
▸ CYP2C19 P33261 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3506032 0.80 CYP1A2 (0.50) CYP1A2CYP3A4CYP2D6CLK4HSD17B10
SCHEMBL6954539 0.77 HTT (0.40) CYP2D6HSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL6959886 0.76 ALDH1A1 (0.53) CYP1A2CYP3A4CYP2D6CLK4HSD17B10
SCHEMBL3504880 0.73 ALDH1A1 (0.56) CYP1A2CYP3A4CYP2D6CLK4HSD17B10
SCHEMBL20460399 0.70 CYP1A2 (0.62) CYP1A2CYP3A4CYP2D6CLK4HSD17B10
SCHEMBL3505036 0.70 ALDH1A1 (0.58) CYP1A2CYP3A4CYP2D6CLK4HSD17B10
SCHEMBL8184622 0.70 CYP3A4 (0.45) CYP1A2CYP3A4CYP2D6CLK4HSD17B10
SCHEMBL3505061 0.69 KDM4E (0.53) HSD17B10LMNAALDH1A1KDM4EMAPT
SCHEMBL3505581 0.69 HSP90AA1 (0.50) CYP1A2CYP3A4CYP2D6CLK4HSD17B10
SCHEMBL9085767 0.69 NR1I3 (0.46) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100247543-A1 TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES ORYZON GENOMICS, S.A. (ES) 2010-09-30 — — US disclosed
EP-0669920-B1 SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS AVENTIS PHARMA INC (US) 2003-02-12 — — EP disclosed
US-6046203-A USEFUL FOR THE TREATMENT OF VARIOUS MEMORY DYSFUNCTIONS CHARACTERIZED BY A DECREASED CHOLINERGIC FUNCTION SUCH AS ALZHEIMER'S DISEASE; ALSO INHIBIT MONOAMINE OXIDASE AND HENCE ARE USEFUL AS ANTIDEPRESSANTS AVENTIS PHARMACEUTICALS INC. (US) 2000-04-04 — — US disclosed
US-5925766-A COGNITION ACTIVATORS FOR DECREASING CHOLINERGIC FUNCTION OF ALZHEIMER*S DISEASE AND ARE ENZYME INHIBITORS OF MONOAMINE OXIDASE AND ARE ANTIDEPRESSANTS HOECHST MARION ROUSSEL, INC. (US) 1999-07-20 — — US disclosed
US-5756754-A Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds HOECHST MARION ROUSSEL, INC. (US) 1998-05-26 — — US disclosed
US-5580982-A ANTIDEPRESSANTS; ANTICHOLINERGIC AGENTS; ALZHEIMER'S DISEASE; AMINE OXIDASE INHIBITORS HOECHST MARION ROUSSEL INC. (US) 1996-12-03 — — US disclosed
US-5494908-A ANTIDEPRESSANT HOECHST-ROUSSEL PHARMACEUTICAL INCORPORATED (US) 1996-02-27 — — US disclosed
Send feedback